| Pregnancy |
1 |
0.59 |
| Borderline Personality Disorder |
0 |
0.93 |
| Oxytocin |
0 |
0.53 |
| Personality Disorders |
0 |
0.5 |
| Anxiety Disorder |
0 |
0.28 |
| Depression |
0 |
0.22 |
| Aggression |
0 |
0.15 |
| Diagnostic and Statistical Manual of Mental Disorders |
0 |
0.15 |
| Anxiety |
0 |
0.12 |
| Deliberate Self-Harm |
0 |
0.11 |
| Antipsychotics |
0 |
0.09 |
| Atypical Antipsychotics |
0 |
0.09 |
| Adverse Effects |
0 |
0.06 |
| Antidepressant drug |
0 |
0.06 |
| Brachial |
0 |
0.06 |
| Central Nervous System |
0 |
0.06 |
| Cognition |
0 |
0.06 |
| Functional Neuroimaging |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Mental Illness |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Plasma |
0 |
0.06 |
| Psychosocial |
0 |
0.06 |
| Psychotherapy |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| NMDA Receptor Antagonist |
0 |
0.05 |
| Addiction |
0 |
0.04 |
| Health Care Services |
0 |
0.04 |
| Substance Abuse |
0 |
0.04 |
| Treatment Guidelines |
0 |
0.04 |
| Abuse |
0 |
0.03 |
| Acute Pain |
0 |
0.03 |
| Adherence |
0 |
0.03 |
| Brain |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.03 |
| Electrophysiology |
0 |
0.03 |
| Fatigue |
0 |
0.03 |
| Food and Drug Administration (FDA) |
0 |
0.03 |
| Health Care Facilities, Manpower, and Services |
0 |
0.03 |
| Involuntary Emotional Expression Disorder |
0 |
0.03 |
| Iowa |
0 |
0.03 |
| Major Depression |
0 |
0.03 |
| Match |
0 |
0.03 |
| Medical Life |
0 |
0.03 |
| Multiple Sclerosis |
0 |
0.03 |
| Neuroimaging |
0 |
0.03 |
| Neurostimulation |
0 |
0.03 |
| Pain Management |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Repetitive Transcranial Magnetic Stimulation |
0 |
0.03 |
| Severity Index |
0 |
0.03 |
| Traumatic Brain Injury |
0 |
0.03 |